121 related articles for article (PubMed ID: 16932372)
1. Does time of onset of therapy alter the protective cardiovascular effect of fluvastatin after renal transplantation?
Morales JM
Nat Clin Pract Nephrol; 2005 Dec; 1(2):78-9. PubMed ID: 16932372
[No Abstract] [Full Text] [Related]
2. Fluvastatin plus fish oil are more effective on cardiovascular risk factors than fluvastatin alone.
Singer P
Prostaglandins Leukot Essent Fatty Acids; 2005 May; 72(5):379-80. PubMed ID: 15850720
[No Abstract] [Full Text] [Related]
3. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study.
Schouten O; Poldermans D; Visser L; Kertai MD; Klein J; van Urk H; Simoons ML; van de Ven LL; Vermeulen M; Bax JJ; Lameris TW; Boersma E
Am Heart J; 2004 Dec; 148(6):1047-52. PubMed ID: 15632892
[No Abstract] [Full Text] [Related]
4. [High therapeutic effect and safety of fluvastatin].
Pharm Unserer Zeit; 2003; 32(6):516-7. PubMed ID: 14639833
[No Abstract] [Full Text] [Related]
5. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Corsini A; Holdaas H
Ren Fail; 2005; 27(3):259-73. PubMed ID: 15957541
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
Holdaas H; Fellström B; Jardine AG; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Logan JO; Staffler B; Gimpelewicz C;
Nephrol Dial Transplant; 2005 May; 20(5):974-80. PubMed ID: 15784644
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of hypercholesterolemia in kidney transplant recipients].
Fritsche L; Budde K; Neumayer HH
Dtsch Med Wochenschr; 2003 Apr; 128(16):879-81. PubMed ID: 12701034
[No Abstract] [Full Text] [Related]
8. Management of dyslipidemia in renal disease and transplantation.
Zolezzi M
Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617
[No Abstract] [Full Text] [Related]
9. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
Fellström B; Abedini S; Holdaas H; Jardine AG; Staffler B; Gimpelewicz C;
Clin Transplant; 2006; 20(6):732-9. PubMed ID: 17100723
[TBL] [Abstract][Full Text] [Related]
10. Serum lipids and hemostasis in kidney allograft recipients treated with fluvastatin (Lescol) for 3 months.
Malyszko JS; Malyszko J; Mysliwiec M
Transplant Proc; 2000 Sep; 32(6):1344-6. PubMed ID: 10995974
[No Abstract] [Full Text] [Related]
11. Fluvastatin: what is the evidence?
Bagg W; Braatvedt G
N Z Med J; 1997 Aug; 110(1050):321-2. PubMed ID: 9315035
[No Abstract] [Full Text] [Related]
12. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial.
Holdaas H; Fellström B; Jardine AG;
Am J Transplant; 2005 Jun; 5(6):1574-5. PubMed ID: 15888072
[No Abstract] [Full Text] [Related]
13. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients.
Kasiske BL;
Am J Transplant; 2005 Jun; 5(6):1576. PubMed ID: 15888073
[No Abstract] [Full Text] [Related]
14. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial.
Serón D; Oppenheimer F; Pallardó LM; Lauzurica R; Errasti P; Gomez-Huertas E; Bosmans JL; Sanchez-Plumed J; Romero R; Marques M; Fulladosa X; Moreso F
Transplantation; 2008 Jul; 86(1):82-7. PubMed ID: 18622282
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure.
Tekin A; Sezgin N; Katircibaşi MT; Tekin G; Cölkesen Y; Sezgin AT; Müderrisoğlu H
Coron Artery Dis; 2008 Nov; 19(7):513-9. PubMed ID: 18923248
[TBL] [Abstract][Full Text] [Related]
16. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin in patients undergoing vascular surgery.
Landesberg G; Beattie SW; Alpert JS
N Engl J Med; 2009 Nov; 361(22):2186-7; author reply 2187-8. PubMed ID: 19950408
[No Abstract] [Full Text] [Related]
18. Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats.
Paragh G; Fóris G; Paragh G; Seres I; Karányi Z; Fülöp P; Balogh Z; Kosztáczky B; Teichmann F; Kertai P
Cancer Lett; 2005 May; 222(1):17-22. PubMed ID: 15837537
[TBL] [Abstract][Full Text] [Related]
19. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).
Dunkelgrun M; Boersma E; Schouten O; Koopman-van Gemert AW; van Poorten F; Bax JJ; Thomson IR; Poldermans D;
Ann Surg; 2009 Jun; 249(6):921-6. PubMed ID: 19474688
[TBL] [Abstract][Full Text] [Related]
20. [Better prognosis for dialysis dependent type 2 diabetic patient. Statin delays arterial onset of arterial stiffness].
MMW Fortschr Med; 2003 Apr; 145(16):60. PubMed ID: 14606406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
